Last reviewed · How we verify
GLPG0555
At a glance
| Generic name | GLPG0555 |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oral Bioavailability of GLPG0555 in Different Solid Formulations (PHASE1)
- Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects (PHASE1)
- First-in-Human Single Ascending and Multiple Dose of GLPG0555 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG0555 CI brief — competitive landscape report
- GLPG0555 updates RSS · CI watch RSS
- Galapagos NV portfolio CI